Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Everolimus and LongActing Octreotide Trial in Polycystic Livers" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Everolimus and LongActing Octreotide Trial in Polycystic Livers for you to read. Along with our medical data and news we also list Everolimus and LongActing Octreotide Trial in Polycystic Livers Clinical Trials, which are updated daily. BioPortfolio also has a large database of Everolimus and LongActing Octreotide Trial in Polycystic Livers Companies for you to search.
Innovent Biologics of Suzhou has begun a US Phase I trial of its anti-CD47 mAb candidate (IBI188) in patients with advanced malignant tumors. By binding to the CD47 antigen on tumor cells, IBI188 is expected to block the CD47-SIRPα signaling pathway, inhibit the "do not eat me" signal, and promote the phagocytosis of tumor cells by macrophages. Innovent called IBI188 a "pivotal product in ou...
[Articles] Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial
Monthly intermittent preventive treatment with dihydroartemisinin–piperaquine was safe but did not lead to significant improvements in birth outcomes compared with sulfadoxine–pyrimethamine.
Long-term treatment with β blockers could increase decompensation-free survival in patients with compensated cirrhosis and CSPH, mainly by reducing the incidence of ascites.
Final results of the STREAM trial were presented at the 2018, 49th Union World Conference on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled trial comparing the 18–24 month WHO-recommended multidrug-resistant tuberculosis (MDR-TB) treatment regimen with a 9–12 month regimen similar to that first described in Bangladesh.1 Under programmatic conditions, the lon...
(The Endocrine Society) Symptoms of polycystic ovary syndrome (PCOS) improved with exposure to healthy bacteria in the gut, according to a study in a mouse model of this common women's endocrine disorder. The study results will be presented Monday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments. ...
I was a small piece in the search to find a cure. Now I feel as if I’m getting erased, and medical science doesn’t have any answers.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, “Biogen”). Clar...
[3/21/2019] The U.S. Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma. FDA reviewed data …
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with plac...
Trial failure raises doubts about amyloid as a target for drug development -- Read more on ScientificAmerican.com
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Conatus and Novartis suffer another midphase NASH flop .Conatus Pharmaceuticals’ emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease drug fail to … Continue reading →
Johnson & Johnson has suspended Phase IIb trial of its RSV asset written off a further $700m against its RSV...
Novartis, Conatus' emricasan fails mid-stage NASH fibrosis trial https://firstwordpharma.com/node/1630929?tsid=28®ion_id=6 …
The trial is run by Precision-Panc, a research program and clinical trials project led by the University of Glasgow with major funding from Cancer Research UK. It brings The post Pancreatic cancer trial in UK achieves patient milestone appeared first on Compelo Medical Devices - Latest industry news and analysis.
Biogen and Eisai have announced they are discontinuing two Phase III trials, Engage and Emerge, evaluating the safety and efficacy...Read More... The post Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds appeared first on Pharmaceutical Technology.
$NVCR Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer https://www.businesswire.com/news/home/20190322005019/en/Novocure-Initiates-Phase-3-Pivotal-Trial-Recurrent …
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor ...
Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation ...
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the...
$CNAT downgraded to Hold at SunTrust after failed ENCORE-NF trial
-#FDA puts multiple myeloma trial on hold after patient deaths -Biogen and Eisai discontinue Phase 3 Alzheimer's trial -Sandoz CEO Richard Francis to step down -Pfizer #CEO Ian Read's pay packet cut from $27.9m to $19.5m http://bit.ly/2U30g5f pic.twitt
- #FDA puts multiple myeloma trial on hold after patient deaths -Biogen and Eisai discontinue Phase 3 Alzheimer's trial -Sandoz CEO Richard Francis to step down -Pfizer #CEO Ian Read's pay packet cut from $27.9m to $19.5m http://bit.ly/2U30g5f pic.twitter.com/RQo2q97Q8B
Final guidance issued by the FDA on stem cell therapy trial design included an assurance from the agency that it will be more -More-
Updated results from GlaxoSmithKline's Phase I clinical trial evaluating its candidate GSK2857916 for multiple myeloma showed -More-
News report People with a certain type of lymphoma will now have access to a targeted cancer drug on the NHS in England. Brentuximab vedotin (Adcetris) was approved by the Nation